Access the full text.
Sign up today, get DeepDyve free for 14 days.
( Newswire.ca , et al. GSK’s JEMPERLI (dostarlimab for injection) approved in Canada as an anti-PD-1 therapy for recurrent or advanced endometrial cancer, https://www.newswire.ca/news-releases/gsk-s-jemperli-dostarlimab-for-injection-approved-in-canada-as-an-anti-pd-1-therapy-for-recurrent-or-advanced-endometrial-cancer-805724726.html (2021, accessed June 2022).)
Newswire.ca , et al. GSK’s JEMPERLI (dostarlimab for injection) approved in Canada as an anti-PD-1 therapy for recurrent or advanced endometrial cancer, https://www.newswire.ca/news-releases/gsk-s-jemperli-dostarlimab-for-injection-approved-in-canada-as-an-anti-pd-1-therapy-for-recurrent-or-advanced-endometrial-cancer-805724726.html (2021, accessed June 2022).Newswire.ca , et al. GSK’s JEMPERLI (dostarlimab for injection) approved in Canada as an anti-PD-1 therapy for recurrent or advanced endometrial cancer, https://www.newswire.ca/news-releases/gsk-s-jemperli-dostarlimab-for-injection-approved-in-canada-as-an-anti-pd-1-therapy-for-recurrent-or-advanced-endometrial-cancer-805724726.html (2021, accessed June 2022)., Newswire.ca , et al. GSK’s JEMPERLI (dostarlimab for injection) approved in Canada as an anti-PD-1 therapy for recurrent or advanced endometrial cancer, https://www.newswire.ca/news-releases/gsk-s-jemperli-dostarlimab-for-injection-approved-in-canada-as-an-anti-pd-1-therapy-for-recurrent-or-advanced-endometrial-cancer-805724726.html (2021, accessed June 2022).
F. Guo, Lyuba Levine, A. Berenson (2021)
Trends in the incidence of endometrial cancer among young women in the United States, 2001 to 2017.Journal of Clinical Oncology, 39
H. Rütten, C. Verhoef, Willem Weelden, A. Smits, Joëlle Dhanis, N. Ottevanger, J. Pijnenborg (2021)
Recurrent Endometrial Cancer: Local and Systemic Treatment OptionsCancers, 13
(2021)
Newswire
( OakninA TinkerAV GilbertL , et al. Clinical activity and safety of the anti–programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair–deficient endometrial cancer: a nonrandomized phase 1 clinical trial. JAMA Oncol 2020; 6: 1766–1772.33001143)
OakninA TinkerAV GilbertL , et al. Clinical activity and safety of the anti–programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair–deficient endometrial cancer: a nonrandomized phase 1 clinical trial. JAMA Oncol 2020; 6: 1766–1772.33001143OakninA TinkerAV GilbertL , et al. Clinical activity and safety of the anti–programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair–deficient endometrial cancer: a nonrandomized phase 1 clinical trial. JAMA Oncol 2020; 6: 1766–1772.33001143, OakninA TinkerAV GilbertL , et al. Clinical activity and safety of the anti–programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair–deficient endometrial cancer: a nonrandomized phase 1 clinical trial. JAMA Oncol 2020; 6: 1766–1772.33001143
FDA grants accelerated approval to dostarlimab-gxly for dMMR endometrial cancer
( FDA.gov. FDA approves pembrolizumab for advanced endometrial carcinoma, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-advanced-endometrial-carcinoma (2022, accessed April 2022).)
FDA.gov. FDA approves pembrolizumab for advanced endometrial carcinoma, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-advanced-endometrial-carcinoma (2022, accessed April 2022).FDA.gov. FDA approves pembrolizumab for advanced endometrial carcinoma, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-advanced-endometrial-carcinoma (2022, accessed April 2022)., FDA.gov. FDA approves pembrolizumab for advanced endometrial carcinoma, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-advanced-endometrial-carcinoma (2022, accessed April 2022).
A. Green, J. Feinberg, V. Makker (2020)
A Review of Immune Checkpoint Blockade Therapy in Endometrial Cancer.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 40
( RubinsteinMM CairdI ZhouQ , et al. A phase II trial of durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial carcinoma and endometrial carcinosarcoma. J Clin Oncol 2019; 37(suppl 15): 5582.)
RubinsteinMM CairdI ZhouQ , et al. A phase II trial of durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial carcinoma and endometrial carcinosarcoma. J Clin Oncol 2019; 37(suppl 15): 5582.RubinsteinMM CairdI ZhouQ , et al. A phase II trial of durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial carcinoma and endometrial carcinosarcoma. J Clin Oncol 2019; 37(suppl 15): 5582., RubinsteinMM CairdI ZhouQ , et al. A phase II trial of durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial carcinoma and endometrial carcinosarcoma. J Clin Oncol 2019; 37(suppl 15): 5582.
( EMA.eu. Lenvima: EMA/CHMP Summary of opinion, https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-lenvima-ii-42_en.pdf (2021, accessed May 2022).)
EMA.eu. Lenvima: EMA/CHMP Summary of opinion, https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-lenvima-ii-42_en.pdf (2021, accessed May 2022).EMA.eu. Lenvima: EMA/CHMP Summary of opinion, https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-lenvima-ii-42_en.pdf (2021, accessed May 2022)., EMA.eu. Lenvima: EMA/CHMP Summary of opinion, https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-lenvima-ii-42_en.pdf (2021, accessed May 2022).
D. O’Malley, G. Bariani, P. Cassier, A. Marabelle, A. Hansen, A. Acosta, W. Miller, T. Safra, A. Italiano, L. Mileshkin, Lei Xu, F. Jin, K. Norwood, M. Maio (2022)
Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 StudyJournal of Clinical Oncology, 40
J. Lortet-Tieulent, J. Ferlay, F. Bray, A. Jemal (2018)
International Patterns and Trends in Endometrial Cancer Incidence, 1978-2013.Journal of the National Cancer Institute, 110 4
T. Tamai, S. Hayato, S. Hojo, Takuya Suzuki, T. Okusaka, K. Ikeda, H. Kumada (2017)
Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure–Response AnalysesJournal of Clinical Pharmacology, 57
K. Tamura, K. Hasegawa, N. Katsumata, Koji Matsumoto, H. Mukai, S. Takahashi, H. Nomura, H. Minami (2019)
Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: Multicenter, open‐label phase 2 trialCancer Science, 110
( Cancer Care Ontario. Cancer fact: endometrial cancer starting to rise in younger women in Ontario, https://www.cancercareontario.ca/en/cancer-facts/endometrial-cancer-starting-rise-younger-women-ontario (2019, accessed February 2022).)
Cancer Care Ontario. Cancer fact: endometrial cancer starting to rise in younger women in Ontario, https://www.cancercareontario.ca/en/cancer-facts/endometrial-cancer-starting-rise-younger-women-ontario (2019, accessed February 2022).Cancer Care Ontario. Cancer fact: endometrial cancer starting to rise in younger women in Ontario, https://www.cancercareontario.ca/en/cancer-facts/endometrial-cancer-starting-rise-younger-women-ontario (2019, accessed February 2022)., Cancer Care Ontario. Cancer fact: endometrial cancer starting to rise in younger women in Ontario, https://www.cancercareontario.ca/en/cancer-facts/endometrial-cancer-starting-rise-younger-women-ontario (2019, accessed February 2022).
( RüttenH VerhoefC van WeeldenWJ , et al. Recurrent endometrial cancer: local and systemic treatment options. Cancers 2021; 13: 6275.34944893)
RüttenH VerhoefC van WeeldenWJ , et al. Recurrent endometrial cancer: local and systemic treatment options. Cancers 2021; 13: 6275.34944893RüttenH VerhoefC van WeeldenWJ , et al. Recurrent endometrial cancer: local and systemic treatment options. Cancers 2021; 13: 6275.34944893, RüttenH VerhoefC van WeeldenWJ , et al. Recurrent endometrial cancer: local and systemic treatment options. Cancers 2021; 13: 6275.34944893
L. Uppendahl, S. Mullany, B. Winterhoff (2017)
Molecular characterization of endometrial cancer and therapeutic implicationsCurrent Opinion in Obstetrics and Gynecology, 29
( Canada.ca. Notice of Compliance with Conditions - Qualifying Notice for Lenvima, https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/notice-compliance/notice-compliance-conditions/qualifying-notice-lenvima-228723.html (2021, accessed May 2022).)
Canada.ca. Notice of Compliance with Conditions - Qualifying Notice for Lenvima, https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/notice-compliance/notice-compliance-conditions/qualifying-notice-lenvima-228723.html (2021, accessed May 2022).Canada.ca. Notice of Compliance with Conditions - Qualifying Notice for Lenvima, https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/notice-compliance/notice-compliance-conditions/qualifying-notice-lenvima-228723.html (2021, accessed May 2022)., Canada.ca. Notice of Compliance with Conditions - Qualifying Notice for Lenvima, https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/notice-compliance/notice-compliance-conditions/qualifying-notice-lenvima-228723.html (2021, accessed May 2022).
Kimberly FNP-C (2022)
Emerging Treatment Options for Advanced or Recurrent Endometrial CancerJournal of the Advanced Practitioner in Oncology
( van RoijJ KiefferJM van de Poll-FranseL , et al. Assessing measurement invariance in the EORTC QLQ-C30. Qual Life Res 2022; 31: 889–901.34327634)
van RoijJ KiefferJM van de Poll-FranseL , et al. Assessing measurement invariance in the EORTC QLQ-C30. Qual Life Res 2022; 31: 889–901.34327634van RoijJ KiefferJM van de Poll-FranseL , et al. Assessing measurement invariance in the EORTC QLQ-C30. Qual Life Res 2022; 31: 889–901.34327634, van RoijJ KiefferJM van de Poll-FranseL , et al. Assessing measurement invariance in the EORTC QLQ-C30. Qual Life Res 2022; 31: 889–901.34327634
( HowJA PatelS FellmanB , et al. Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer. Gynecol Oncol 2021; 162: 24–31.33958211)
HowJA PatelS FellmanB , et al. Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer. Gynecol Oncol 2021; 162: 24–31.33958211HowJA PatelS FellmanB , et al. Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer. Gynecol Oncol 2021; 162: 24–31.33958211, HowJA PatelS FellmanB , et al. Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer. Gynecol Oncol 2021; 162: 24–31.33958211
Joyce Liu, M. Gordon, J. Veneris, F. Braiteh, A. Balmanoukian, J. Eder, A. Oaknin, E. Hamilton, Yulei Wang, Indrani Sarkar, L. Molinero, M. Fassò, C. O'Hear, Yvonne Lin, L. Emens (2019)
Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers.Gynecologic oncology
( National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Uterine neoplasms, http://wwwnccnorg/professionals/physician_gls/PDF/uterinepdf (2022, accessed February 2022).)
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Uterine neoplasms, http://wwwnccnorg/professionals/physician_gls/PDF/uterinepdf (2022, accessed February 2022).National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Uterine neoplasms, http://wwwnccnorg/professionals/physician_gls/PDF/uterinepdf (2022, accessed February 2022)., National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Uterine neoplasms, http://wwwnccnorg/professionals/physician_gls/PDF/uterinepdf (2022, accessed February 2022).
( MakkerV TaylorMH OakninA , et al. Characterization and management of adverse reactions in patients with advanced endometrial carcinoma treated with lenvatinib plus pembrolizumab. Oncologist 2021; 26: e1599–e1608.)
MakkerV TaylorMH OakninA , et al. Characterization and management of adverse reactions in patients with advanced endometrial carcinoma treated with lenvatinib plus pembrolizumab. Oncologist 2021; 26: e1599–e1608.MakkerV TaylorMH OakninA , et al. Characterization and management of adverse reactions in patients with advanced endometrial carcinoma treated with lenvatinib plus pembrolizumab. Oncologist 2021; 26: e1599–e1608., MakkerV TaylorMH OakninA , et al. Characterization and management of adverse reactions in patients with advanced endometrial carcinoma treated with lenvatinib plus pembrolizumab. Oncologist 2021; 26: e1599–e1608.
( WinterhoffB ThomaierL MullanyS , et al. Molecular characterization of endometrial cancer and therapeutic implications. Curr Opin Obstet Gynecol 2020; 32: 76–83.31851045)
WinterhoffB ThomaierL MullanyS , et al. Molecular characterization of endometrial cancer and therapeutic implications. Curr Opin Obstet Gynecol 2020; 32: 76–83.31851045WinterhoffB ThomaierL MullanyS , et al. Molecular characterization of endometrial cancer and therapeutic implications. Curr Opin Obstet Gynecol 2020; 32: 76–83.31851045, WinterhoffB ThomaierL MullanyS , et al. Molecular characterization of endometrial cancer and therapeutic implications. Curr Opin Obstet Gynecol 2020; 32: 76–83.31851045
N. Abu-Rustum, C. Yashar, Sarah Bean, Kristin Bradley, Susan Campos, Hye Chon, Christina Chu, David Cohn, M. Crispens, Shari Damast, Oliver Dorigo, P. Eifel, Christine Fisher, Peter Frederick, David Gaffney, Ernest Han, W. Huh, J. Lurain, Andrea Mariani, David Mutch, Christa Nagel, Larissa Nekhlyudov, A. Fader, S. Remmenga, R. Reynolds, Rachel Sisodia, T. Tillmanns, Stefanie Ueda, E. Wyse, Nicole Mcmillian, Jillian Scavone (2019)
Gestational Trophoblastic Neoplasia, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.Journal of the National Comprehensive Cancer Network : JNCCN, 17 11
Anne-Michelle Slater (2012)
OpinionEnvironmental Law Review, 14
( ConcinN Matias-GuiuX VergoteI , et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer 2021; 31: 12–39.33397713)
ConcinN Matias-GuiuX VergoteI , et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer 2021; 31: 12–39.33397713ConcinN Matias-GuiuX VergoteI , et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer 2021; 31: 12–39.33397713, ConcinN Matias-GuiuX VergoteI , et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer 2021; 31: 12–39.33397713
D. Dong, H. Lei, Duanya Liu, Hansong Bai, Yue Yang, B. Tang, Ke Li, Juan Liu, Gang Xu, Xue Xiao (2021)
POLE and Mismatch Repair Status, Checkpoint Proteins and Tumor-Infiltrating Lymphocytes in Combination, and Tumor Differentiation: Identify Endometrial Cancers for ImmunotherapyFrontiers in Oncology, 11
A. Oaknin, L. Gilbert, A. Tinker, Jubilee Brown, C. Mathews, Joshua Press, R. Sabatier, D. O’Malley, V. Samouélian, V. Boni, L. Duska, S. Ghamande, P. Ghatage, R. Kristeleit, C. Iii, W. Guo, E. Im, S. Zildjian, Xinwei Han, T. Duan, J. Veneris, B. Pothuri (2022)
Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm studyJournal for Immunotherapy of Cancer, 10
V. Makker, Matthew Taylor, A. Oaknin, A. Herráez, R. Orlowski, L. Dutta, M. Ren, Melissa Zale, D. O’Malley (2021)
Characterization and Management of Adverse Reactions in Patients with Advanced Endometrial Carcinoma Treated with Lenvatinib Plus PembrolizumabThe Oncologist, 26
B. Rimel (2021)
A randomized, phase ii study comparing single-agent olaparib, single agent cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent or metastatic endometrial cancerGynecologic Oncology
( TamaiT HayatoS HojoS , et al. Dose finding of lenvatinib in subjects with advanced hepatocellular carcinoma based on population pharmacokinetic and exposure–response analyses. J Clin Pharmacol 2017; 57: 1138–1147.28561918)
TamaiT HayatoS HojoS , et al. Dose finding of lenvatinib in subjects with advanced hepatocellular carcinoma based on population pharmacokinetic and exposure–response analyses. J Clin Pharmacol 2017; 57: 1138–1147.28561918TamaiT HayatoS HojoS , et al. Dose finding of lenvatinib in subjects with advanced hepatocellular carcinoma based on population pharmacokinetic and exposure–response analyses. J Clin Pharmacol 2017; 57: 1138–1147.28561918, TamaiT HayatoS HojoS , et al. Dose finding of lenvatinib in subjects with advanced hepatocellular carcinoma based on population pharmacokinetic and exposure–response analyses. J Clin Pharmacol 2017; 57: 1138–1147.28561918
D. Lorusso, N. Colombo, A. Herráez, A. Santin, E. Colomba, D. Miller, K. Fujiwara, S. Pignata, S. Baron-Hay, I. Ray-Coquard, R. Shapira-Frommer, Y. Kim, M. McCormack, R. Massaad, A. Nguyen, Q. Zhao, J. McKenzie, V. Prabhu, V. Makker (2022)
20MO Time to deterioration in quality of life in patients (pts) with advanced endometrial cancer (aEC) treated with lenvatinib plus pembrolizumab (L+P) or treatment of physician’s choice (TPC)Annals of Oncology
D. Pfister, K. Ang, D. Brizel (2012)
National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology
D. Berton, Susana Banerjee, G. Curigliano, S. Cresta, H. Arkenau, C. Abdeddaim, R. Kristeleit, A. Redondo, C. Leath, A. Torres, W. Guo, E. Im, T. André (2021)
Antitumor activity of dostarlimab in patients with mismatch repair-deficient/microsatellite instability–high tumors: A combined analysis of two cohorts in the GARNET study.Journal of Clinical Oncology, 39
S. Lheureux, D. Matei, P. Konstantinopoulos, M. Block, A. Jewell, S. Gaillard, M. McHale, C. McCourt, S. Temkin, E. Girda, F. Backes, T. Werner, L. Duska, S. Kehoe, Lisa Wang, R. Wildman, Ben Wang, P. Ohashi, J. Wright, G. Fleming (2020)
A randomized phase II study of cabozantinib and nivolumab versus nivolumab in recurrent endometrial cancer.Journal of Clinical Oncology, 38
A. Bricou, S. Bendifallah, Mathilde Daix-Moreux, L. Ouldamer, V. Lavoué, A. Benbara, C. Huchon, G. Canlorbe, E. Raimond, C. Coutant, O. Graesslin, P. Collinet, X. Carcopino, C. Touboul, E. Daraï, L. Carbillon, M. Ballester (2018)
A Proposal for a Classification for Recurrent Endometrial Cancer: Analysis of a French Multicenter Database From the FRANCOGYN Study GroupInternational Journal of Gynecologic Cancer, 28
R. Brooks, G. Fleming, R. Lastra, N. Lee, J. Moroney, C. Son, K. Tatebe, J. Veneris (2019)
Current recommendations and recent progress in endometrial cancerCA: A Cancer Journal for Clinicians, 69
K. Takayasu, S. Arii, M. Kudo, T. Ichida, O. Matsui, N. Izumi, Y. Matsuyama, M. Sakamoto, O. Nakashima, Y. Ku, N. Kokudo, M. Makuuchi (2012)
Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines.Journal of hepatology, 56 4
P. Ott, Y. Bang, D. Berton-Rigaud, E. Élez, M. Pishvaian, H. Rugo, I. Puzanov, J. Mehnert, K. Aung, Juanita Lopez, M. Carrigan, S. Saraf, Mei Chen, J. Soria (2017)
Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 35 22
GSK's JEMPERLI (dostarlimab for injection) approved in Canada as an anti-PD-1 therapy for recurrent or advanced endometrial cancer
J. Roij, J. Kieffer, L. Poll-Franse, O. Husson, N. Raijmakers, J. Gelissen (2021)
Assessing measurement invariance in the EORTC QLQ-C30Quality of Life Research, 31
( KonstantinopoulosPA LuoW LiuJF , et al. Phase II study of avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent/persistent endometrial cancer. J Clin Oncol 2019; 37: 2786–2794.31461377)
KonstantinopoulosPA LuoW LiuJF , et al. Phase II study of avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent/persistent endometrial cancer. J Clin Oncol 2019; 37: 2786–2794.31461377KonstantinopoulosPA LuoW LiuJF , et al. Phase II study of avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent/persistent endometrial cancer. J Clin Oncol 2019; 37: 2786–2794.31461377, KonstantinopoulosPA LuoW LiuJF , et al. Phase II study of avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent/persistent endometrial cancer. J Clin Oncol 2019; 37: 2786–2794.31461377
( LiuJF GordonM VenerisJ , et al. Safety, clinical activity and biomarker assessments of atezolizumab from a phase I study in advanced/recurrent ovarian and uterine cancers. Gynecol Oncol 2019; 154: 314–322.31204078)
LiuJF GordonM VenerisJ , et al. Safety, clinical activity and biomarker assessments of atezolizumab from a phase I study in advanced/recurrent ovarian and uterine cancers. Gynecol Oncol 2019; 154: 314–322.31204078LiuJF GordonM VenerisJ , et al. Safety, clinical activity and biomarker assessments of atezolizumab from a phase I study in advanced/recurrent ovarian and uterine cancers. Gynecol Oncol 2019; 154: 314–322.31204078, LiuJF GordonM VenerisJ , et al. Safety, clinical activity and biomarker assessments of atezolizumab from a phase I study in advanced/recurrent ovarian and uterine cancers. Gynecol Oncol 2019; 154: 314–322.31204078
F. Legge, S. Restaino, L. Leone, V. Carone, C. Ronsini, G. Fiore, T. Pasciuto, Silvia Pelligra, F. Ciccarone, G. Scambia, F. Fanfani (2019)
Clinical outcome of recurrent endometrial cancer: analysis of post-relapse survival by pattern of recurrence and secondary treatmentInternational Journal of Gynecological Cancer, 30
( JamiesonA BosseT McAlpineJN . The emerging role of molecular pathology in directing the systemic treatment of endometrial cancer. Ther Adv Med Oncol 2021; 13: 17588359211035959.)
JamiesonA BosseT McAlpineJN . The emerging role of molecular pathology in directing the systemic treatment of endometrial cancer. Ther Adv Med Oncol 2021; 13: 17588359211035959.JamiesonA BosseT McAlpineJN . The emerging role of molecular pathology in directing the systemic treatment of endometrial cancer. Ther Adv Med Oncol 2021; 13: 17588359211035959., JamiesonA BosseT McAlpineJN . The emerging role of molecular pathology in directing the systemic treatment of endometrial cancer. Ther Adv Med Oncol 2021; 13: 17588359211035959.
FDA approval of Keytruda (pembrolizumab) in combination with Lenvima (lenvatinib) for advanced endometrial carcinoma
(2020)
Phase 2 trial of lenvatinib at 2 starting doses+ everolimus in renal cell carcinoma
Y. Antill, P. Kok, K. Robledo, S. Yip, M. Cummins, Deborah Smith, A. Spurdle, E. Barnes, Y. Lee, M. Friedlander, S. Baron-Hay, C. Shannon, J. Coward, P. Beale, G. Goss, T. Meniawy, J. Lombard, John Andrews, M. Stockler, L. Mileshkin (2021)
Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trialJournal for Immunotherapy of Cancer, 9
( AntillY KokP-S RobledoK , et al. Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial. J Immunother Cancer 2021; 9: e002255.)
AntillY KokP-S RobledoK , et al. Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial. J Immunother Cancer 2021; 9: e002255.AntillY KokP-S RobledoK , et al. Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial. J Immunother Cancer 2021; 9: e002255., AntillY KokP-S RobledoK , et al. Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial. J Immunother Cancer 2021; 9: e002255.
S. Bellone, D. Roque, E. Siegel, N. Buza, P. Hui, E. Bonazzoli, Adele Guglielmi, L. Zammataro, N. Nagarkatti, S. Zaidi, Jungsoo Lee, D. Silasi, Gloria Huang, V. Andikyan, S. Damast, M. Clark, M. Azodi, P. Schwartz, J. Tymon-Rosario, J. Harold, D. Mauricio, B. Zeybek, G. Menderes, G. Altwerger, E. Ratner, L. Alexandrov, A. Iwasaki, Y. Kong, E. Song, W. Dong, J. Elvin, Jungmin Choi, A. Santin (2021)
A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instabilityCancer, 128
( ColomboN LorussoD Casado HerráezA , et al. 726MO–outcomes by histology and prior therapy with lenvatinib plus pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer (study 309/KEYNOTE-775). Ann Oncol 2021; 32: S725–S772.)
ColomboN LorussoD Casado HerráezA , et al. 726MO–outcomes by histology and prior therapy with lenvatinib plus pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer (study 309/KEYNOTE-775). Ann Oncol 2021; 32: S725–S772.ColomboN LorussoD Casado HerráezA , et al. 726MO–outcomes by histology and prior therapy with lenvatinib plus pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer (study 309/KEYNOTE-775). Ann Oncol 2021; 32: S725–S772., ColomboN LorussoD Casado HerráezA , et al. 726MO–outcomes by histology and prior therapy with lenvatinib plus pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer (study 309/KEYNOTE-775). Ann Oncol 2021; 32: S725–S772.
( TakayasuK AriiS KudoM , et al. Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. J Hepatol 2012; 56: 886–892.22173160)
TakayasuK AriiS KudoM , et al. Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. J Hepatol 2012; 56: 886–892.22173160TakayasuK AriiS KudoM , et al. Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. J Hepatol 2012; 56: 886–892.22173160, TakayasuK AriiS KudoM , et al. Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. J Hepatol 2012; 56: 886–892.22173160
N. Concin, X. Matías-Guiu, I. Vergote, D. Cibula, M. Mirza, S. Marnitz, J. Ledermann, T. Bosse, Cyrus Chargari, A. Fagotti, C. Fotopoulou, A. Martín, S. Lax, D. Lorusso, C. Marth, P. Morice, R. Nout, D. O'Donnell, D. Querleu, M. Raspollini, J. Sehouli, A. Sturdza, Alexandra Taylor, A. Westermann, P. Wimberger, N. Colombo, F. Planchamp, C. Creutzberg (2020)
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinomaInternational Journal of Gynecological Cancer, 31
J. Dudley, Ming-Tseh Lin, D. Le, J. Eshleman (2016)
Microsatellite Instability as a Biomarker for PD-1 BlockadeClinical Cancer Research, 22
( MitricC BernardiniMQ . Endometrial cancer: transitioning from histology to genomics. Curr Oncol 2022; 29: 741–757.35200562)
MitricC BernardiniMQ . Endometrial cancer: transitioning from histology to genomics. Curr Oncol 2022; 29: 741–757.35200562MitricC BernardiniMQ . Endometrial cancer: transitioning from histology to genomics. Curr Oncol 2022; 29: 741–757.35200562, MitricC BernardiniMQ . Endometrial cancer: transitioning from histology to genomics. Curr Oncol 2022; 29: 741–757.35200562
( LheureuxS MateiD KonstantinopoulosPA , et al. A randomized phase II study of cabozantinib and nivolumab versus nivolumab in recurrent endometrial cancer. J Clin Oncol 2020; 38 (Suppl. 15): 6010.)
LheureuxS MateiD KonstantinopoulosPA , et al. A randomized phase II study of cabozantinib and nivolumab versus nivolumab in recurrent endometrial cancer. J Clin Oncol 2020; 38 (Suppl. 15): 6010.LheureuxS MateiD KonstantinopoulosPA , et al. A randomized phase II study of cabozantinib and nivolumab versus nivolumab in recurrent endometrial cancer. J Clin Oncol 2020; 38 (Suppl. 15): 6010., LheureuxS MateiD KonstantinopoulosPA , et al. A randomized phase II study of cabozantinib and nivolumab versus nivolumab in recurrent endometrial cancer. J Clin Oncol 2020; 38 (Suppl. 15): 6010.
Andrew Knight (1881)
JournalsThe American Journal of Dental Science, 14
( DongD LeiH LiuD , et al. POLE and mismatch repair status, checkpoint proteins and tumor-infiltrating lymphocytes in combination, and tumor differentiation: identify endometrial cancers for immunotherapy. Front Oncol 2021; 11: 640018.33816285)
DongD LeiH LiuD , et al. POLE and mismatch repair status, checkpoint proteins and tumor-infiltrating lymphocytes in combination, and tumor differentiation: identify endometrial cancers for immunotherapy. Front Oncol 2021; 11: 640018.33816285DongD LeiH LiuD , et al. POLE and mismatch repair status, checkpoint proteins and tumor-infiltrating lymphocytes in combination, and tumor differentiation: identify endometrial cancers for immunotherapy. Front Oncol 2021; 11: 640018.33816285, DongD LeiH LiuD , et al. POLE and mismatch repair status, checkpoint proteins and tumor-infiltrating lymphocytes in combination, and tumor differentiation: identify endometrial cancers for immunotherapy. Front Oncol 2021; 11: 640018.33816285
( BertonD BanerjeeSN CuriglianoG , et al. Antitumor activity of dostarlimab in patients with mismatch repair-deficient/microsatellite instability–high tumors: a combined analysis of two cohorts in the GARNET study. J Clin Oncol, 2021; 39(Suppl. 15): 2564.)
BertonD BanerjeeSN CuriglianoG , et al. Antitumor activity of dostarlimab in patients with mismatch repair-deficient/microsatellite instability–high tumors: a combined analysis of two cohorts in the GARNET study. J Clin Oncol, 2021; 39(Suppl. 15): 2564.BertonD BanerjeeSN CuriglianoG , et al. Antitumor activity of dostarlimab in patients with mismatch repair-deficient/microsatellite instability–high tumors: a combined analysis of two cohorts in the GARNET study. J Clin Oncol, 2021; 39(Suppl. 15): 2564., BertonD BanerjeeSN CuriglianoG , et al. Antitumor activity of dostarlimab in patients with mismatch repair-deficient/microsatellite instability–high tumors: a combined analysis of two cohorts in the GARNET study. J Clin Oncol, 2021; 39(Suppl. 15): 2564.
C. Mitric, M. Bernardini (2022)
Endometrial Cancer: Transitioning from Histology to GenomicsCurrent Oncology, 29
A. Hanks (2002)
CanadaJournal of Industrial Hemp, 7
Madhura Deshpande, P. Romanski, Z. Rosenwaks, Jeannine Gerhardt (2020)
Gynecological Cancers Caused by Deficient Mismatch Repair and Microsatellite InstabilityCancers, 12
B. Sorbe, H. Andersson, K. Boman, P. Rosenberg, M. Kalling (2008)
Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel— long‐ term follow‐ upInternational Journal of Gynecological Cancer, 18
( OnstadMA SchmandtRE LuKH . Addressing the role of obesity in endometrial cancer risk, prevention, and treatment. J Clin Oncol 2016; 34: 4225.27903150)
OnstadMA SchmandtRE LuKH . Addressing the role of obesity in endometrial cancer risk, prevention, and treatment. J Clin Oncol 2016; 34: 4225.27903150OnstadMA SchmandtRE LuKH . Addressing the role of obesity in endometrial cancer risk, prevention, and treatment. J Clin Oncol 2016; 34: 4225.27903150, OnstadMA SchmandtRE LuKH . Addressing the role of obesity in endometrial cancer risk, prevention, and treatment. J Clin Oncol 2016; 34: 4225.27903150
( MillerDS FiliaciVL MannelRS , et al. Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG oncology/GOG0209). J Clin Oncol 2020; 38: 3841–3850.33078978)
MillerDS FiliaciVL MannelRS , et al. Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG oncology/GOG0209). J Clin Oncol 2020; 38: 3841–3850.33078978MillerDS FiliaciVL MannelRS , et al. Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG oncology/GOG0209). J Clin Oncol 2020; 38: 3841–3850.33078978, MillerDS FiliaciVL MannelRS , et al. Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG oncology/GOG0209). J Clin Oncol 2020; 38: 3841–3850.33078978
( MarabelleA LeDT AsciertoPA , et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair–deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 2020; 38: 1–10.31682550)
MarabelleA LeDT AsciertoPA , et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair–deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 2020; 38: 1–10.31682550MarabelleA LeDT AsciertoPA , et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair–deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 2020; 38: 1–10.31682550, MarabelleA LeDT AsciertoPA , et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair–deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 2020; 38: 1–10.31682550
S. Bellone, D. Roque, E. Siegel, N. Buza, P. Hui, E. Bonazzoli, A. Guglielmi, L. Zammataro, N. Nagarkatti, S. Zaidi, J. Lee, D. Silasi, G. Huang, V. Andikyan, S. Damast, M. Clark, M. Azodi, P. Schwartz, J. Tymon-Rosario, J. Harold, D. Mauricio, B. Zeybek, G. Menderes, G. Altwerger, E. Ratner, L. Alexandrov, A. Iwasaki, Y. Kong, E. Song, W. Dong, J. Elvin, J. Choi, A. Santin (2021)
A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793).Annals of oncology : official journal of the European Society for Medical Oncology
K. Malagari, M. Pomoni, H. Moschouris, Evanthia Bouma, J. Koskinas, A. Stefaniotou, A. Marinis, A. Kelekis, E. Alexopoulou, A. Chatziioannou, Katerina Chatzimichael, S. Dourakis, N. Kelekis, S. Rizos, D. Kelekis (2012)
Chemoembolization With Doxorubicin-Eluting Beads for Unresectable Hepatocellular Carcinoma: Five-Year Survival AnalysisCardioVascular and Interventional Radiology, 35
( SungH FerlayJ SiegelRL , et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209–249.33538338)
SungH FerlayJ SiegelRL , et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209–249.33538338SungH FerlayJ SiegelRL , et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209–249.33538338, SungH FerlayJ SiegelRL , et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209–249.33538338
MA Onstad, RE Schmandt, KH Lu (2016)
Addressing the role of obesity in endometrial cancer risk, prevention, and treatmentJ Clin Oncol, 34
( LorussoD ColomboN HerraezAC , et al. 20MO time to deterioration in quality of life in patients (pts) with advanced endometrial cancer (aEC) treated with lenvatinib plus pembrolizumab (L+P) or treatment of physician’s choice (TPC). Ann Oncol 2022; 33: S391–S392.)
LorussoD ColomboN HerraezAC , et al. 20MO time to deterioration in quality of life in patients (pts) with advanced endometrial cancer (aEC) treated with lenvatinib plus pembrolizumab (L+P) or treatment of physician’s choice (TPC). Ann Oncol 2022; 33: S391–S392.LorussoD ColomboN HerraezAC , et al. 20MO time to deterioration in quality of life in patients (pts) with advanced endometrial cancer (aEC) treated with lenvatinib plus pembrolizumab (L+P) or treatment of physician’s choice (TPC). Ann Oncol 2022; 33: S391–S392., LorussoD ColomboN HerraezAC , et al. 20MO time to deterioration in quality of life in patients (pts) with advanced endometrial cancer (aEC) treated with lenvatinib plus pembrolizumab (L+P) or treatment of physician’s choice (TPC). Ann Oncol 2022; 33: S391–S392.
( RoqueDM BelloneS SiegelER , et al. A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793). J Clin Oncol, 2021; 39(Suppl. 15): 5523.)
RoqueDM BelloneS SiegelER , et al. A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793). J Clin Oncol, 2021; 39(Suppl. 15): 5523.RoqueDM BelloneS SiegelER , et al. A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793). J Clin Oncol, 2021; 39(Suppl. 15): 5523., RoqueDM BelloneS SiegelER , et al. A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793). J Clin Oncol, 2021; 39(Suppl. 15): 5523.
( MalagariK PomoniM MoschourisH , et al. Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: five-year survival analysis. Cardiovasc Intervent Radiol 2012; 35: 1119–1128.22614031)
MalagariK PomoniM MoschourisH , et al. Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: five-year survival analysis. Cardiovasc Intervent Radiol 2012; 35: 1119–1128.22614031MalagariK PomoniM MoschourisH , et al. Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: five-year survival analysis. Cardiovasc Intervent Radiol 2012; 35: 1119–1128.22614031, MalagariK PomoniM MoschourisH , et al. Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: five-year survival analysis. Cardiovasc Intervent Radiol 2012; 35: 1119–1128.22614031
P. Konstantinopoulos, A. Gockley, N. Xiong, N. Tayob, C. Krasner, M. Buss, S. Campos, S. Schumer, A. Wright, Joyce Liu, M. Shea, Y. Oladapo, Cesar Castro, M. Polak, C. Whalen, S. Bouberhan, S. Cannistra, R. Penson, G. Fleming, U. Matulonis (2020)
LBA35 Phase II study of PARP inhibitor talazoparib and PD-L1 inhibitor avelumab in patients (pts) with microsatellite stable (MSS) recurrent/persistent endometrial cancerAnnals of Oncology, 31
( RimelB . A randomized, phase II study comparing single-agent olaparib, single agent cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent or metastatic endometrial cancer. Gynecol Oncol 2021; 162: S43–S44.)
RimelB . A randomized, phase II study comparing single-agent olaparib, single agent cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent or metastatic endometrial cancer. Gynecol Oncol 2021; 162: S43–S44.RimelB . A randomized, phase II study comparing single-agent olaparib, single agent cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent or metastatic endometrial cancer. Gynecol Oncol 2021; 162: S43–S44., RimelB . A randomized, phase II study comparing single-agent olaparib, single agent cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent or metastatic endometrial cancer. Gynecol Oncol 2021; 162: S43–S44.
( TamuraK HasegawaK KatsumataN , et al. Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: multicenter, open-label phase 2 trial. Cancer Sci 2019; 110: 2894–2904.31348579)
TamuraK HasegawaK KatsumataN , et al. Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: multicenter, open-label phase 2 trial. Cancer Sci 2019; 110: 2894–2904.31348579TamuraK HasegawaK KatsumataN , et al. Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: multicenter, open-label phase 2 trial. Cancer Sci 2019; 110: 2894–2904.31348579, TamuraK HasegawaK KatsumataN , et al. Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: multicenter, open-label phase 2 trial. Cancer Sci 2019; 110: 2894–2904.31348579
A. Jamieson, T. Bosse, J. McAlpine (2021)
The emerging role of molecular pathology in directing the systemic treatment of endometrial cancerTherapeutic Advances in Medical Oncology, 13
( SorbeB AnderssonH BomanK , et al. Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel—long-term follow-up. Int J Gynecol Cancer 2008; 18: 803–808.17944917)
SorbeB AnderssonH BomanK , et al. Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel—long-term follow-up. Int J Gynecol Cancer 2008; 18: 803–808.17944917SorbeB AnderssonH BomanK , et al. Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel—long-term follow-up. Int J Gynecol Cancer 2008; 18: 803–808.17944917, SorbeB AnderssonH BomanK , et al. Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel—long-term follow-up. Int J Gynecol Cancer 2008; 18: 803–808.17944917
( Canada.ca. Keytruda - Notice of Compliance with Conditions - Qualifying Notice, https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/notice-compliance/conditions/keytruda-qualifying-notice-218779.html (2020, accessed June 2022).)
Canada.ca. Keytruda - Notice of Compliance with Conditions - Qualifying Notice, https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/notice-compliance/conditions/keytruda-qualifying-notice-218779.html (2020, accessed June 2022).Canada.ca. Keytruda - Notice of Compliance with Conditions - Qualifying Notice, https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/notice-compliance/conditions/keytruda-qualifying-notice-218779.html (2020, accessed June 2022)., Canada.ca. Keytruda - Notice of Compliance with Conditions - Qualifying Notice, https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/notice-compliance/conditions/keytruda-qualifying-notice-218779.html (2020, accessed June 2022).
( BricouA BendifallahS Daix-MoreuxM , et al. A proposal for a classification for recurrent endometrial cancer: analysis of a French multicenter database from the FRANCOGYN Study Group. Int J Gynecol Cancer 2018; 28: 1278–1284.29994907)
BricouA BendifallahS Daix-MoreuxM , et al. A proposal for a classification for recurrent endometrial cancer: analysis of a French multicenter database from the FRANCOGYN Study Group. Int J Gynecol Cancer 2018; 28: 1278–1284.29994907BricouA BendifallahS Daix-MoreuxM , et al. A proposal for a classification for recurrent endometrial cancer: analysis of a French multicenter database from the FRANCOGYN Study Group. Int J Gynecol Cancer 2018; 28: 1278–1284.29994907, BricouA BendifallahS Daix-MoreuxM , et al. A proposal for a classification for recurrent endometrial cancer: analysis of a French multicenter database from the FRANCOGYN Study Group. Int J Gynecol Cancer 2018; 28: 1278–1284.29994907
( DudleyJC LinM-T LeDT , et al. Microsatellite instability as a biomarker for PD-1 blockade. Clin Cancer Res 2016; 22: 813–820.26880610)
DudleyJC LinM-T LeDT , et al. Microsatellite instability as a biomarker for PD-1 blockade. Clin Cancer Res 2016; 22: 813–820.26880610DudleyJC LinM-T LeDT , et al. Microsatellite instability as a biomarker for PD-1 blockade. Clin Cancer Res 2016; 22: 813–820.26880610, DudleyJC LinM-T LeDT , et al. Microsatellite instability as a biomarker for PD-1 blockade. Clin Cancer Res 2016; 22: 813–820.26880610
Joyce Liu, N. Xiong, S. Campos, A. Wright, C. Krasner, S. Schumer, N. Horowitz, J. Veneris, N. Tayob, S. Morrissey, Gabriela West, Roxanne Quinn, U. Matulonis, P. Konstantinopoulos (2021)
Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous CarcinomaJournal of Clinical Oncology, 39
V. Makker, N. Colombo, A. Herráez, A. Santin, E. Colomba, D. Miller, K. Fujiwara, S. Pignata, S. Baron-Hay, I. Ray-Coquard, R. Shapira-Frommer, K. Ushijima, J. Sakata, K. Yonemori, Y. Kim, E. Guerra, U. Sanli, M. McCormack, Alan Smith, S. Keefe, Steven Bird, L. Dutta, R. Orlowski, D. Lorusso (2022)
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.The New England journal of medicine
( GuoF LevineL BerensonA . Trends in the incidence of endometrial cancer among young women in the United States, 2001 to 2017. J Clin Oncol 2021; 39: 5578.)
GuoF LevineL BerensonA . Trends in the incidence of endometrial cancer among young women in the United States, 2001 to 2017. J Clin Oncol 2021; 39: 5578.GuoF LevineL BerensonA . Trends in the incidence of endometrial cancer among young women in the United States, 2001 to 2017. J Clin Oncol 2021; 39: 5578., GuoF LevineL BerensonA . Trends in the incidence of endometrial cancer among young women in the United States, 2001 to 2017. J Clin Oncol 2021; 39: 5578.
G. Fleming (2015)
Second-Line Therapy for Endometrial Cancer: The Need for Better Options.Obstetrical & Gynecological Survey
( FlemingGF . Second-line therapy for endometrial cancer: the need for better options. Obstet Gynecol Surv 2016; 71: 406–408.)
FlemingGF . Second-line therapy for endometrial cancer: the need for better options. Obstet Gynecol Surv 2016; 71: 406–408.FlemingGF . Second-line therapy for endometrial cancer: the need for better options. Obstet Gynecol Surv 2016; 71: 406–408., FlemingGF . Second-line therapy for endometrial cancer: the need for better options. Obstet Gynecol Surv 2016; 71: 406–408.
D. Miller, V. Filiaci, G. Fleming, R. Mannel, D. Cohn, Takashi Matsumoto, K. Tewari, P. DiSilvestro, M. Pearl, R. Zaino (2012)
Late-Breaking Abstract 1: Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group studyGynecologic Oncology, 125
( BrooksRA FlemingGF LastraRR , et al. Current recommendations and recent progress in endometrial cancer. CA Cancer J Clin 2019; 69: 258–279.31074865)
BrooksRA FlemingGF LastraRR , et al. Current recommendations and recent progress in endometrial cancer. CA Cancer J Clin 2019; 69: 258–279.31074865BrooksRA FlemingGF LastraRR , et al. Current recommendations and recent progress in endometrial cancer. CA Cancer J Clin 2019; 69: 258–279.31074865, BrooksRA FlemingGF LastraRR , et al. Current recommendations and recent progress in endometrial cancer. CA Cancer J Clin 2019; 69: 258–279.31074865
( OttPA BangY-J Berton-RigaudD , et al. Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1–positive endometrial cancer: results from the KEYNOTE-028 study. J Clin Oncol 2017; 35: 2535–2541.28489510)
OttPA BangY-J Berton-RigaudD , et al. Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1–positive endometrial cancer: results from the KEYNOTE-028 study. J Clin Oncol 2017; 35: 2535–2541.28489510OttPA BangY-J Berton-RigaudD , et al. Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1–positive endometrial cancer: results from the KEYNOTE-028 study. J Clin Oncol 2017; 35: 2535–2541.28489510, OttPA BangY-J Berton-RigaudD , et al. Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1–positive endometrial cancer: results from the KEYNOTE-028 study. J Clin Oncol 2017; 35: 2535–2541.28489510
A. Oaknin, A. Tinker, L. Gilbert, V. Samouëlian, C. Mathews, Jubilee Brown, M. Barretina-Ginesta, V. Moreno, A. Gravina, C. Abdeddaim, Susana Banerjee, Wei Guo, H. Danaee, E. Im, R. Sabatier (2020)
Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial CancerJAMA Oncology, 6
Keytruda -Notice of Compliance with Conditions -Qualifying Notice
E. Shaw, M. Farris, Jessica McNeil, C. Friedenreich (2016)
Obesity and Endometrial Cancer.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 208
( Lortet-TieulentJ FerlayJ BrayF , et al. International patterns and trends in endometrial cancer incidence, 1978–2013. J Natl Cancer Inst 2018; 110: 354–361.29045681)
Lortet-TieulentJ FerlayJ BrayF , et al. International patterns and trends in endometrial cancer incidence, 1978–2013. J Natl Cancer Inst 2018; 110: 354–361.29045681Lortet-TieulentJ FerlayJ BrayF , et al. International patterns and trends in endometrial cancer incidence, 1978–2013. J Natl Cancer Inst 2018; 110: 354–361.29045681, Lortet-TieulentJ FerlayJ BrayF , et al. International patterns and trends in endometrial cancer incidence, 1978–2013. J Natl Cancer Inst 2018; 110: 354–361.29045681
( LeggeF RestainoS LeoneL , et al. Clinical outcome of recurrent endometrial cancer: analysis of post-relapse survival by pattern of recurrence and secondary treatment. Int J Gynecol Cancer 2020; 30: 193–200.31792085)
LeggeF RestainoS LeoneL , et al. Clinical outcome of recurrent endometrial cancer: analysis of post-relapse survival by pattern of recurrence and secondary treatment. Int J Gynecol Cancer 2020; 30: 193–200.31792085LeggeF RestainoS LeoneL , et al. Clinical outcome of recurrent endometrial cancer: analysis of post-relapse survival by pattern of recurrence and secondary treatment. Int J Gynecol Cancer 2020; 30: 193–200.31792085, LeggeF RestainoS LeoneL , et al. Clinical outcome of recurrent endometrial cancer: analysis of post-relapse survival by pattern of recurrence and secondary treatment. Int J Gynecol Cancer 2020; 30: 193–200.31792085
( MillerD FiliaciV FlemingG , et al. Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2012; 125: 771.)
MillerD FiliaciV FlemingG , et al. Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2012; 125: 771.MillerD FiliaciV FlemingG , et al. Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2012; 125: 771., MillerD FiliaciV FlemingG , et al. Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2012; 125: 771.
A. Marabelle, D. Le, P. Ascierto, A. Giacomo, A. Jesus-Acosta, J. Delord, R. Geva, M. Gottfried, N. Penel, A. Hansen, S. Piha-Paul, T. Doi, B. Gao, H. Chung, J. López-Martín, Y. Bang, R. Frommer, M. Shah, R. Ghori, A. Joe, S. Pruitt, L. Diaz (2020)
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology
J. How, Shrina Patel, B. Fellman, K. Lu, P. Hwu, L. Ramondetta, S. Westin, N. Fleming, P. Soliman, A. Jazaeri (2021)
Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer.Gynecologic oncology
H. Sung, J. Ferlay, R. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal, F. Bray (2021)
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesCA: A Cancer Journal for Clinicians, 71
M. Rubinstein, Imogen Caird, Qin Zhou, A. Iasonos, C. Friedman, K. Cadoo, J. Konner, R. O’Cearbhaill, W. Tew, D. Zamarin, R. Grisham, C. Kyi, Krysten Soldan, S. Lichtman, L. Ligresti, S. Schweber, J. Singh, T. Troso-Sandoval, C. Aghajanian, V. Makker (2019)
A phase II trial of durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial carcinoma and endometrial carcinosarcoma.Journal of Clinical Oncology
( HallaK . Emerging treatment options for advanced or recurrent endometrial cancer. J Adv Pract Oncol 2022; 13: 45.)
HallaK . Emerging treatment options for advanced or recurrent endometrial cancer. J Adv Pract Oncol 2022; 13: 45.HallaK . Emerging treatment options for advanced or recurrent endometrial cancer. J Adv Pract Oncol 2022; 13: 45., HallaK . Emerging treatment options for advanced or recurrent endometrial cancer. J Adv Pract Oncol 2022; 13: 45.
D. Miller, V. Filiaci, R. Mannel, D. Cohn, Takashi Matsumoto, K. Tewari, P. DiSilvestro, M. Pearl, P. Argenta, M. Powell, S. Zweizig, D. Warshal, P. Hanjani, M. Carney, Helen Huang, D. Cella, R. Zaino, G. Fleming (2020)
Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209).Journal of clinical oncology : official journal of the American Society of Clinical Oncology
( KonstantinopoulosP GockleyA XiongN , et al. LBA35 phase II study of PARP inhibitor talazoparib and PD-L1 inhibitor avelumab in patients (PTS) with microsatellite stable (MSS) recurrent/persistent endometrial cancer. Ann Oncol 2020; 31: S1165.)
KonstantinopoulosP GockleyA XiongN , et al. LBA35 phase II study of PARP inhibitor talazoparib and PD-L1 inhibitor avelumab in patients (PTS) with microsatellite stable (MSS) recurrent/persistent endometrial cancer. Ann Oncol 2020; 31: S1165.KonstantinopoulosP GockleyA XiongN , et al. LBA35 phase II study of PARP inhibitor talazoparib and PD-L1 inhibitor avelumab in patients (PTS) with microsatellite stable (MSS) recurrent/persistent endometrial cancer. Ann Oncol 2020; 31: S1165., KonstantinopoulosP GockleyA XiongN , et al. LBA35 phase II study of PARP inhibitor talazoparib and PD-L1 inhibitor avelumab in patients (PTS) with microsatellite stable (MSS) recurrent/persistent endometrial cancer. Ann Oncol 2020; 31: S1165.
P. Konstantinopoulos, W. Luo, Joyce Liu, D. Gulhan, C. Krasner, J. Ishizuka, A. Gockley, M. Buss, W. Growdon, H. Crowe, S. Campos, N. Lindeman, S. Hill, E. Stover, S. Schumer, A. Wright, J. Curtis, Roxanne Quinn, C. Whalen, K. Gray, R. Penson, S. Cannistra, G. Fleming, U. Matulonis (2019)
Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology
N. Colombo, D. Lorusso, A. Herráez, A. Santin, E. Colomba, D. Miller, K. Fujiwara, S. Pignata, A. Floquet, B. Monk, Susana Banerjee, R. Penson, R. Kristeleit, M. Fabbro, M. Orlando, H. Mackay, E. Jensen, L. Dutta, R. Orlowski, V. Makker (2021)
726MO Outcomes by histology and prior therapy with lenvatinib plus pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer (Study 309/KEYNOTE-775)Annals of Oncology
( PalS PuenteJ HengD . Phase 2 trial of lenvatinib at 2 starting doses+ everolimus in renal cell carcinoma (RCC). International Kidney Cancer Symposium (IKCS), Miami, FL, 6-7 November 2020.)
PalS PuenteJ HengD . Phase 2 trial of lenvatinib at 2 starting doses+ everolimus in renal cell carcinoma (RCC). International Kidney Cancer Symposium (IKCS), Miami, FL, 6-7 November 2020.PalS PuenteJ HengD . Phase 2 trial of lenvatinib at 2 starting doses+ everolimus in renal cell carcinoma (RCC). International Kidney Cancer Symposium (IKCS), Miami, FL, 6-7 November 2020., PalS PuenteJ HengD . Phase 2 trial of lenvatinib at 2 starting doses+ everolimus in renal cell carcinoma (RCC). International Kidney Cancer Symposium (IKCS), Miami, FL, 6-7 November 2020.
M. Onstad, R. Schmandt, K. Lu (2016)
Addressing the Role of Obesity in Endometrial Cancer Risk, Prevention, and Treatment.Obstetrical & Gynecological Survey
( O’MalleyDM BarianiGM CassierPA , et al. Pembrolizumab in patients with microsatellite instability–high advanced endometrial cancer: results from the KEYNOTE-158 study. J Clin Oncol 2022; 40: 752–761.34990208)
O’MalleyDM BarianiGM CassierPA , et al. Pembrolizumab in patients with microsatellite instability–high advanced endometrial cancer: results from the KEYNOTE-158 study. J Clin Oncol 2022; 40: 752–761.34990208O’MalleyDM BarianiGM CassierPA , et al. Pembrolizumab in patients with microsatellite instability–high advanced endometrial cancer: results from the KEYNOTE-158 study. J Clin Oncol 2022; 40: 752–761.34990208, O’MalleyDM BarianiGM CassierPA , et al. Pembrolizumab in patients with microsatellite instability–high advanced endometrial cancer: results from the KEYNOTE-158 study. J Clin Oncol 2022; 40: 752–761.34990208
Visit SAGE journals online journals.sagepub.com/ home/tam
( DeshpandeM RomanskiPA RosenwaksZ , et al. Gynecological cancers caused by deficient mismatch repair and microsatellite instability. Cancers 2020; 12: 3319.33182707)
DeshpandeM RomanskiPA RosenwaksZ , et al. Gynecological cancers caused by deficient mismatch repair and microsatellite instability. Cancers 2020; 12: 3319.33182707DeshpandeM RomanskiPA RosenwaksZ , et al. Gynecological cancers caused by deficient mismatch repair and microsatellite instability. Cancers 2020; 12: 3319.33182707, DeshpandeM RomanskiPA RosenwaksZ , et al. Gynecological cancers caused by deficient mismatch repair and microsatellite instability. Cancers 2020; 12: 3319.33182707
( ShawE FarrisM McNeilJ , et al. Obesity and endometrial cancer. Recent Results Cancer Res 2016; 208: 107–136.27909905)
ShawE FarrisM McNeilJ , et al. Obesity and endometrial cancer. Recent Results Cancer Res 2016; 208: 107–136.27909905ShawE FarrisM McNeilJ , et al. Obesity and endometrial cancer. Recent Results Cancer Res 2016; 208: 107–136.27909905, ShawE FarrisM McNeilJ , et al. Obesity and endometrial cancer. Recent Results Cancer Res 2016; 208: 107–136.27909905
S. Lheureux, D. Matei, P. Konstantinopoulos, Ben Wang, Ramy Gadalla, M. Block, A. Jewell, S. Gaillard, M. McHale, C. McCourt, Sarah Temkin, E. Girda, F. Backes, T. Werner, L. Duska, S. Kehoe, I. Colombo, Lisa Wang, Xuan Li, Rachel Wildman, S. Soleimani, S. Lien, J. Wright, Trevor Pugh, P. Ohashi, D. Brooks, G. Fleming (2022)
Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancerJournal for Immunotherapy of Cancer, 10
N. Hunnings (1897)
OntarioThe Journal of Comparative Medicine and Veterinary Archives, 18
( GreenAK FeinbergJ MakkerV . A review of immune checkpoint blockade therapy in endometrial cancer. Am Soc Clin Oncol Edu Book 2020; 40: 1–7.)
GreenAK FeinbergJ MakkerV . A review of immune checkpoint blockade therapy in endometrial cancer. Am Soc Clin Oncol Edu Book 2020; 40: 1–7.GreenAK FeinbergJ MakkerV . A review of immune checkpoint blockade therapy in endometrial cancer. Am Soc Clin Oncol Edu Book 2020; 40: 1–7., GreenAK FeinbergJ MakkerV . A review of immune checkpoint blockade therapy in endometrial cancer. Am Soc Clin Oncol Edu Book 2020; 40: 1–7.
( FDA.gov , et al. FDA grants accelerated approval to dostarlimab-gxly for dMMR endometrial cancer, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dostarlimab-gxly-dmmr-endometrial-cancer (2021, accessed February 2022).)
FDA.gov , et al. FDA grants accelerated approval to dostarlimab-gxly for dMMR endometrial cancer, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dostarlimab-gxly-dmmr-endometrial-cancer (2021, accessed February 2022).FDA.gov , et al. FDA grants accelerated approval to dostarlimab-gxly for dMMR endometrial cancer, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dostarlimab-gxly-dmmr-endometrial-cancer (2021, accessed February 2022)., FDA.gov , et al. FDA grants accelerated approval to dostarlimab-gxly for dMMR endometrial cancer, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dostarlimab-gxly-dmmr-endometrial-cancer (2021, accessed February 2022).
( BelloneS RoqueDM SiegelER , et al. A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability. Cancer 2022; 128: 1206–1218.34875107)
BelloneS RoqueDM SiegelER , et al. A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability. Cancer 2022; 128: 1206–1218.34875107BelloneS RoqueDM SiegelER , et al. A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability. Cancer 2022; 128: 1206–1218.34875107, BelloneS RoqueDM SiegelER , et al. A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability. Cancer 2022; 128: 1206–1218.34875107
( FDA.gov. FDA approval of Keytruda (pembrolizumab) in combination with Lenvima (lenvatinib) for advanced endometrial carcinoma, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-keytruda-pembrolizumab-combination-lenvima-lenvatinib-advanced (2021, accessed May 2022).)
FDA.gov. FDA approval of Keytruda (pembrolizumab) in combination with Lenvima (lenvatinib) for advanced endometrial carcinoma, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-keytruda-pembrolizumab-combination-lenvima-lenvatinib-advanced (2021, accessed May 2022).FDA.gov. FDA approval of Keytruda (pembrolizumab) in combination with Lenvima (lenvatinib) for advanced endometrial carcinoma, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-keytruda-pembrolizumab-combination-lenvima-lenvatinib-advanced (2021, accessed May 2022)., FDA.gov. FDA approval of Keytruda (pembrolizumab) in combination with Lenvima (lenvatinib) for advanced endometrial carcinoma, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-keytruda-pembrolizumab-combination-lenvima-lenvatinib-advanced (2021, accessed May 2022).
Background and objectives:Endometrial cancer is a common malignancy and recurrences can be fatal. Although platinum-pretreated endometrial tumors are commonly treated with anthracyclines and taxanes, there is no current standard of care. Both immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) have been extensively assessed in this setting, including tumors selected for DNA mismatch repair (MMR)/microsatellite instability (MSI) and programmed death-ligand 1 expression status. This review will provide evidence-based guidance on use of ICIs alone or in combination with TKIs in patients with pretreated advanced, persistent, or recurrent metastatic endometrial cancer.Data sources and methods:Randomized phase II–III trials in unselected populations pretreated, recurrent, or metastatic endometrial cancer and phase I–II trials in biomarker selected populations were identified from PubMed as well as conference proceedings using the key search terms ‘immune checkpoint inhibitors’, ‘endometrial cancer’, and ‘advanced’.Results:A total of nine eligible studies were identified assessing ICI monotherapy for biomarker-selected or ICI plus TKI combinations and a dual ICI regimen for biomarker-unselected patients with pretreated recurrent or metastatic endometrial cancer. In MMR/MSI-selected tumors, five phase I/II studies evaluated ICI monotherapy indicating benefit in these patients. Only the phase III KEYNOTE-775 trial reported a statistically significant overall survival improvement for the combination of pembrolizumab plus lenvatinib compared with docetaxel or paclitaxel regardless of MMR/MSI status.Conclusions:Pembrolizumab plus lenvatinib is indicated for patients with unselected pretreated metastatic endometrial cancer and pembrolizumab monotherapy is a preferred option for patients with MMRd/MSI-H tumors.
Therapeutic Advances in Medical Oncology – SAGE
Published: Mar 1, 2023
Keywords: advanced; biomarker selection; endometrial cancer; immune checkpoint inhibitors; metastatic; pretreated
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.